

Jason Gotlib

Professor of Medicine (Hematology)

Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Hematology Division**

269 Campus Dr Rm 1155

MC 5156

Stanford, CA 94305

Tel (650) 723-9729 Fax (650) 724-5203

Bio

CLINICAL FOCUS

- Cancer > Hematology
- Hematology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Hematology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Charles Dorsey Armstrong Award for Excellence in Patient Care, Stanford Internal Medicine Residency Program (1998)
- Hematology Division Faculty Teaching Award, Stanford Division of Hematology/Department of Medicine (2005, 2007, 2009)
- NIH K23 Mentored Patient-Oriented Research Career Development Award (#HL04409), National Institutes of Health (2001-2006)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2024)
- Medical Education: Stanford University School of Medicine (1995) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2003) CA
- Residency: Stanford University Internal Medicine Residency (1998) CA
- Internship: Stanford University Internal Medicine Residency (1996) CA
- B.A., Franklin & Marshall College , Biology; HAPOS (1990)
- M.D., Stanford , Medicine (1995)
- M.S., Stanford , Clinical Epidemiology (2003)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:

--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs

CLINICAL TRIALS

- (QUANTUM-WILD) (QUIZARTINIB OR PLACEBO PLUS CHEMOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD N, Recruiting
- A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms, Recruiting
- Observational Retrospective Avapritinib Compared w/BestAvailable Tx in AdvancedSystemic Mastocytosis, Recruiting
- Phase I Open-Label Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms, Recruiting
- Phase II CGT9486 as a Single Agent in Advanced Systemic Mastocytosis, Recruiting
- Phase II Ruxolitinib in Idiopathic Hypereosinophilic Syndrome & Primary Eosinophilic Disorders, Recruiting
- Phase III Bomedemstat(MK-3543/IMG-7289) vs Best Available Therapy (BAT) in Essential Thrombocythemia, Recruiting
- PhaseII TL-895 Myelofibrosis JAKi IntolerantMyelofibrosis JAKi TxIneligibleMyelofibrosis orISM, Recruiting
- A Phase II Study of Ibrutinib in Advanced Systemic Mastocytosis, Not Recruiting
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies, Not Recruiting
- Biomarker To Evaluate protein Profiles of neutropnic Fever/Infection with Acute or Chronic Leukemias, Not Recruiting
- Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk, Not Recruiting
- Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis, Not Recruiting
- Expanded Access to Mepolizumab in Hypereosinophilic Syndrome, Not Recruiting
- Extended Tx in Subjects Continuing to Benefit from Ibrutinib After Completion of Ibrutinib CT, Not Recruiting
- ExtendedAccess Momelotinib in PMF /Post-polycythemiaVera /Post-EssentialThrombocythemiaMyelofibrosis, Not Recruiting
- Investigation of Dysregulated Signaling in MPD via Multiparameter Phospho-specific Flow Cytometry, Not Recruiting
- Open-Label Study of SAR302503 Long-Term Effects for Primary or Secondary Myelofibrosis, Not Recruiting
- Phase I BLU-285 in Advanced Systemic Mastocytosis (advSM) &Relapsed /Refractory Myeloid Malignancies, Not Recruiting
- Phase I TG101348 for Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis, Not Recruiting
- Phase I/II CLT-008 after Post-Remission Therapy for High Risk Leukemia or MDS, Not Recruiting
- Phase I/II CYT387 in Primary Myelofibrosis or Post-PV or Post-ET/PV MF, Not Recruiting
- Phase I/II INCB000928 +/- Ruxolitinib in Participants w/ Anemia Due to Myeloproliferative Disorders, Not Recruiting
- Phase I/II SL-401 in Advanced High Risk Myeloproliferative Neoplasms, Not Recruiting
- Phase I/II Venetoclax + Ibrutinib in Relapsed or Refractory CLL & Small Lymphocytic Leukemia, Not Recruiting
- Phase IA/II oral AMN107 in Imatinib-Resistant CML, Ph+ ALL, and Other Hematologic Malignancies, Not Recruiting
- Phase Ib Idelalisib&Ruxolitinib as Tx in PMF /Post-PV MF /Post-ET MF w/Progressive /Relapsed Disease, Not Recruiting
- Phase II ABT-199 (GDC-0199) in CLL w/ Relapse or Refractory to BCR Signaling Pathway Inhibitor Tx, Not Recruiting
- Phase II Avapritinib (BLU-285) in Indolent & Smoldering Systemic Mastocytosis, Not Recruiting
- Phase II Avapritinib (BLU-285) KIT Mutation-targeted TKI in Advanced Systemic Mastocytosis, Not Recruiting

- Phase II Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis +/- AHNMD, Not Recruiting
- Phase II CYT387 in Myelofibrosis/Post-Polycythemia Vera/Post-Essential Thrombocythemia Myelofibrosis, Not Recruiting
- Phase II GS-6624 in Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis, Not Recruiting
- Phase II Hepcidin Mimetic PTG-300 in Phlebotomy-Requiring Polycythemia Vera, Not Recruiting
- Phase II Imetelstat in Intermediate-2 / High-Risk MF Relapsed/Refractory to Janus Kinase Inhibitor, Not Recruiting
- Phase II INCB054828 in Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Not Recruiting
- Phase II LBH589, a Novel deacetylase Inhibitor (DACi) for PMF, ET and PV Myelofibrosis, Not Recruiting
- Phase II Luspatercept (ACE-536) in Myeloproliferative Neoplasm-Associated Myelofibrosis & Anemia +/-, Not Recruiting
- Phase II Midostaurin in ASM or MCL +/- Associated Hematological Clonal Non-Mast Cell Lineage Disease, Not Recruiting
- Phase II Momelotinib PMF, Post-PV Myelofibrosis, Post-ET Myelofibrosis, PV, or ET, Not Recruiting
- Phase II Pacritinib in Myeloproliferative Disorders Previously Treated with Ruxolitinib, Not Recruiting
- Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia, Not Recruiting
- Phase II PRM-151 In Primary Myelofibrosis (PMF), post-PV MF or post-ET MF, Not Recruiting
- Phase II Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R, Not Recruiting
- Phase II Study IPI-926 in Myelofibrosis, Not Recruiting
- Phase II/III KRT-232 in PMF, Post-PV-MF or Post-ET-MF who're Relapsed/Refractory to JAK Inhibitor Tx, Not Recruiting
- Phase III Bendamustine +Rituximab vs Ibrutinib +Rituximab vs Ibrutinib Alone in CLL, Not Recruiting
- Phase III Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera, Not Recruiting
- Phase III Ibrutinib Plus Obinutuzumab vs Ibrutinib Plus Venetoclax & Obinutuzumab in CLL, Not Recruiting
- Phase III Luspatercept (ACE-536) vs Placebo in Anemia Due to IPSS-R Very Low /Low /Intmtd Risk MDS , Not Recruiting
- Phase III Momelotinib vs. Ruxolitinib in PMF / Post-PV/ET Myelofibrosis, Not Recruiting
- Phase III Obinutuzumab +/- Chlorambucil, ACP-196 +/- Obinutuzumab & ACP-196 Monotherapy in CLL, Not Recruiting
- Phase III ON 01910.Na in MDS with Excess Blasts after Relapsed/Refractory/Intolerant to 5-AZC or DAC, Not Recruiting
- Phase III Oral Pacritinib vs Best Available Tx in Thrombocytopenia & PMF /PPVMF /Post-ET MF, Not Recruiting
- Phase III PEGASYS vs Hydroxyurea in High Risk Polycythemia Vera or Essential Thrombocythemia, Not Recruiting
- Phase III SAR302503 in Primary/ Post Polycythemia Vera/ Post Essential Thrombocythemia Myelofibrosis, Not Recruiting
- Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia, Not Recruiting
- Randomized, Double-Blind, Placebo-Controlled Study of INCB018424 for PMF, PPV-MF or PET-MF, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Epidemiology (Masters Program)

Publications

PUBLICATIONS

- **Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Lubke, J., Schwaab, J., Naumann, N., Horny, H., Weiss, C., Metzgeroth, G., Kreil, S., Cross, N. C., Sotlar, K., Fabarius, A., Hofmann, W., Valent, P., Gotlib, et al
2022: JCO2101849

- **Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.** *Cancers*
Youn, M., Smith, S. M., Lee, A. G., Chae, H., Spiteri, E., Erdmann, J., Galperin, I., Jones, L. M., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N., Dahl, et al
1800; 13 (24)
- **Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.** *Nature medicine*
DeAngelo, D. J., Radia, D. H., George, T. I., Robinson, W. A., Quiery, A. T., Drummond, M. W., Bose, P., Hexner, E. O., Winton, E. F., Horny, H., Tugnait, M., Schmidt-Kittler, O., Evans, et al
2021
- **Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.** *Nature medicine*
Gotlib, J., Reiter, A., Radia, D. H., Deininger, M. W., George, T. I., Panse, J., Vannucchi, A. M., Platzbecker, U., Alvarez-Twose, I., Mital, A., Hermine, O., Dybedal, I., Hexner, et al
2021
- **Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal** *HEMASPHERE*
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Nidoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., Elberink, H., Butterfield, J. H., George, et al
2021; 5 (11)
- **Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.** *HemaSphere*
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Nidoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., Elberink, H. O., Butterfield, J. H., George, et al
2021; 5 (11): e646
- **Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms** *CELL REPORTS MEDICINE*
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., Rowley, J., Gotlib, J., Zehnder, J., Krishnan, A.
2021; 2 (10)
- **Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.** *Cell reports. Medicine*
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., Rowley, J., Gotlib, J., Zehnder, J., Krishnan, A.
2021; 2 (10): 100425
- **Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.** *Leukemia*
Zanotti, R., Bonifacio, M., Lucchini, G., Sperr, W. R., Scaffidi, L., van Anrooij, B., Oude Elberink, H. N., Rossignol, J., Hermine, O., Gorska, A., Lange, M., Hadzijusufovic, E., Miething, et al
2021
- **World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management.** *American journal of hematology*
Shomali, W., Gotlib, J.
2021
- **Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.** *Blood advances*
Chen, J. A., Hou, Y., Roskin, K. M., Arber, D. A., Bangs, C. D., Baughn, L. B., Cherry, A. M., Ewalt, M. D., Fire, A. Z., Fresard, L., Kearney, H. M., Montgomery, S. B., Ohgami, et al
2021; 5 (17): 3492-3496
- **Efficacy and Safety of <= 200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies**
Radia, D., DeAngelo, D., Deininger, M. W., Reiter, A., Sen, J., Lin, H., Dimitrijevic, S., Gotlib, J.
CIG MEDIA GROUP, LP.2021: S367-S368
- **Chronic Eosinophilic Leukemia: Diagnosis and Therapy**
Gotlib, J., Shomali, W., Reiter, A.
CIG MEDIA GROUP, LP.2021: S27-S29
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment**
Reiter, A., Cross, N. C. P., Gotlib, J.

CIG MEDIA GROUP, LP.2021: S66-S68

- **Current and future status of JAK inhibitors** *LANCET*
McLornan, D. P., Pope, J. E., Gotlib, J., Harrison, C. N.
2021; 398 (10302): 803-816
- **Diagnosis and Management of Neutrophilic Myeloid Neoplasms** *CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY*
Schwede, M., Gotlib, J., Shomali, W.
2021; 19 (7): 450-459
- **A Phase 1/2 Study of INCB00928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).**
Oh, S. T., Kiladjian, J., Palandri, F., Gotlib, J. R., Mohan, S., Ali, H., Asatiani, E., Seguy, F., Zhou, F., Verstovsek, S.
AMER ASSOC CANCER RESEARCH.2021
- **PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM).**
DeAngelo, D. J., Reiter, A., Radia, D., Deininger, M. W., George, T. I., Panse, J., Vannucchi, A. M., Jentzsch, M., Alvarez-Twose, I., Mital, A., Hermine, O., Dybedal, I., Hexner, et al
AMER ASSOC CANCER RESEARCH.2021
- **Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.** *British journal of haematology*
Naumann, N., Lubke, J., Shomali, W., Reiter, L., Horny, H., Jawhar, M., Dangelo, V., Fabarius, A., Metzgeroth, G., Kreil, S., Sotlar, K., Oni, C., Harrison, et al
2021
- **Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.** *Leukemia research*
Tremblay, D., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M., Kuykendall, A., O'Connell, C., Shammo, J. M., Fleischman, A., Mesa, R., Yacoub, A., Hoffman, R., Moshier, et al
2021; 109: 106629
- **Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).** *Blood advances*
Han, S. Y., Mrozek, K., Voutsinas, J., Wu, Q., Morgan, E. A., Vestergaard, H., Ohgami, R., Kluin, P. M., Kristensen, T. K., Pullarkat, S., Moller, M. B., Schiefer, A., Baughn, et al
2021; 5 (10): 2481-2489
- **Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).** *Leukemia research*
Taylor, F., Li, X., Yip, C., Padilla, B., Mar, B., Green, T., Oren, R., Boral, A. L., Lin, H., Shields, A. L., Gotlib, J.
2021; 108: 106606
- **Avapritinib induces responses in patients with advanced systemic mastocytosis, regardless of prior midostaurin therapy**
Radia, D., Drummond, M. W., Gotlib, J., George, T. I., Quiery, A. T., Winton, E., Lin, H., Mar, B. G., Deininger, M. W., DeAngelo, D. J.
WILEY.2021: 58-59
- **Results from PIONEER: a randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis**
Radia, D. H., Sabato, V., Castells, M., Akin, C., Elberink, H., Tashi, T., George, T. I., Roche, M., DeAngelo, D. J., Gotlib, J.
WILEY.2021: 8-9
- **A Phase 1/2 Study of INCB00928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)**
Oh, S., Kiladjian, J., Palandri, F., Gotlib, J., Mohan, S., Ali, H., Asatiani, E., Seguy, F., Zhou, F., Verstovsek, S.
WILEY.2021: 111-112
- **Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.** *International journal of molecular sciences*
Shomali, W., Gotlib, J.
2021; 22 (6)
- **Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.** *The Journal of allergy and clinical immunology*

- Gotlib, J., George, T., Carter, M. C., Austen, K. F., Bochner, B., Dwyer, D., Lyons, J., Hamilton, M. J., Butterfield, J., Bonadonna, P., Weiler, C., Galli, S. J., Schwartz, et al
2021
- **Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM).** *The Journal of investigative dermatology*
Aberer, E., Sperr, W. R., Bretterklieber, A., Avian, A., Hadzijusufovic, E., Kluijn-Nelemans, H. C., Elberink, H. O., van Anrooij, B., Niedoszytko, M., Lange, M., Gorska, A., Elena, C., Brazzelli, et al
2021
 - **What your HalphaT says about you.** *Blood*
Gotlib, J.
2021; 137 (2): 151–53
 - **Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors.** *Proceedings of the National Academy of Sciences of the United States of America*
Cui, L., Moraga, I., Lerbs, T., Van Neste, C., Wilmes, S., Tsutsumi, N., Trotman-Grant, A. C., Gakovic, M., Andrews, S., Gotlib, J., Darmanis, S., Enge, M., Quake, et al
2021; 118 (2)
 - **Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis** *THERANOSTICS*
Kluijn-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., Illerhaus, A., Elberink, H., Gorska, A., Niedoszytko, M., Lange, M., Scaffidi, L., Zanotti, et al
2021; 11 (1): 292–303
 - **A novel activating JAK1 mutation in chronic eosinophilic leukemia.** *Blood advances*
Shomali, W., Damnernsawad, A., Theparee, T., Sampson, D., Morrow, Q., Yang, F., Fernandez-Pol, S., Press, R. D., Zehnder, J. L., Tyner, J. W., Gotlib, J. R.
2021
 - **Diagnosis and management of neutrophilic myeloid neoplasms.** *Clinical advances in hematology & oncology : H&O*
Schwede, M., Gotlib, J., Shomali, W.
2021; 19 (7): 450-459
 - **Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.** *The journal of allergy and clinical immunology. In practice*
Gulen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N., Butterfield, J. H., Sperr, W. R., Alvarez-Twose, I., Horny, et al
2021
 - **COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM).** *The journal of allergy and clinical immunology. In practice*
Bonadonna, P. n., Brockow, K. n., Niedoszytko, M. n., Elberink, H. O., Akin, C. n., Nedoszytko, B. n., Butterfield, J. H., Alvarez-Twose, I. n., Sotlar, K. n., Schwaab, J. n., Jawhar, M. n., Castells, M. n., Sperr, et al
2021
 - **Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.** *The Lancet. Haematology*
Muñoz-González, J. I., Álvarez-Twose, I. n., Jara-Acevedo, M. n., Zanotti, R. n., Perkins, C. n., Jawhar, M. n., Sperr, W. R., Shoumariyeh, K. n., Schwaab, J. n., Greiner, G. n., Henriques, A. n., Caldas, C. n., Fernández-Giménez, et al
2021
 - **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*
Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.
2021: 1–6
 - **Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.** *Theranostics*
Kluijn-Nelemans, H. C., Jawhar, M., Reiter, A., van Anrooij, B., Gotlib, J., Hartmann, K., Illerhaus, A., Oude Elberink, H. N., Gorska, A., Niedoszytko, M., Lange, M., Scaffidi, L., Zanotti, et al
2021; 11 (1): 292-303
 - **Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors** *Proceedings of the National Academy of Sciences*

- Wernig, G.
2021; 118 (2) (Jan 2021)
- **Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin.** *The journal of allergy and clinical immunology. In practice*
Fuchs, D., Kilbertus, A., Kofler, K., von Bubnoff, N., Shoumariyeh, K., Zanotti, R., Bonadonna, P., Scaffidi, L., Doubek, M., Elberink, H. O., Span, L. F., Hermine, O., Elena, et al
2020
 - **Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFR α -Associated Myeloid Neoplasm With Eosinophilia.** *HemaSphere*
Jain, J., Weinzierl, E. P., Saxe, D., Bergsagel, J., Gotlib, J., Reiter, A., Raikar, S. S.
2020; 4 (6): e486
 - **Practical Management of Adverse Events in Patients With Advanced Systemic Mastocytosis Receiving Midostaurin.** *Expert opinion on biological therapy*
Gotlib, J., Kluin-Nelemans, H. C., Akin, C., Hartmann, K., Valent, P., Reiter, A.
2020
 - **Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure.** *International journal of laboratory hematology*
Ustun, C., Morgan, E. A., Ritz, E. M., Vestergaard, H., Pullarkat, S., Kluin, P. M., Ohgami, R., Baughn, L. B., Kim, Y., Ku, N. K., Czuchlewski, D., Boe Moller, M., Schiefer, et al
2020
 - **Dynamic and Time-To-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naive Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib**
McLornan, D., Mesa, R., Catalano, J., Cervantes, F., Devos, T., Egyed, M., Gotlib, J., Kiladjan, J., Oh, S., Shimoda, K., Coart, E., D'Hollander, K., Donahue, et al
CIG MEDIA GROUP, LP.2020: S329–S330
 - **Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.** *Clinical lymphoma, myeloma & leukemia*
Coltoff, A., Mesa, R., Gotlib, J., Shulman, J., Rampal, R. K., Siwoski, O., Yacoub, A., Moliterno, A., Yang, A., Braunstein, E., Gerds, A. T., Hobbs, G. S., Winton, et al
2020
 - **Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology.** *Blood reviews*
Ozturk, K., Cayci, Z., Gotlib, J., Akin, C., George, T. I., Ustun, C.
2020: 100693
 - **Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.** *Blood*
Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O'Connell, C., Shammo, J., Fleischman, A. G., Scherber, R. M., Mesa, R., Yacoub, A., Perkins, C., Meckstroth, et al
2020
 - **MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis**
Jawhar, M., Schwaab, J., Alvarez-Twose, I., Shoumariyeh, K., Naumann, N., Luebke, J., Perkins, C., Munoz-Gonzalez, J. I., Meggendorfer, M., Kennedy, V., Metzgeroth, G., Fabarius, A., Pfeifer, et al
KARGER.2020: 107–8
 - **New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis.** *Blood*
Reiter, A. n., George, T. I., Gotlib, J. R.
2020
 - **Clinical Features and Survival of Patients with Indolent Systemic Mastocytosis defined by the Updated WHO Classification.** *Allergy*
Trizuljak, J. n., Sperr, W. R., Nekvindová, L. n., Oude Elberink, H. n., Gleixner, K. V., Gorska, A. n., Lange, M. n., Hartmann, K. n., Illerhaus, A. n., Bonifacio, M. n., Perkins, C. n., Elena, C. n., Malcovati, et al
2020
 - **Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.** *Leukemia & lymphoma*

- Azizi, A. n., Ediriwickrema, A. n., Dutta, R. n., Patel, S. A., Shomali, W. n., Medeiros, B. n., Iberri, D. n., Gotlib, J. n., Mannis, G. n., Greenberg, P. n., Majeti, R. n., Zhang, T. n.
2020: 1–8
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Gerds, A. T., Gotlib, J., Bose, P., Deininger, M. W., Dunbar, A., Elshoury, A., George, T. I., Gojo, I., Gundabolu, K., Hexner, E., Hobbs, G., Jain, T., Jamieson, et al
2020; 18 (9): 1248–69
 - **Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts.** *Theranostics*
Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., Sotlar, K., Sperr, W. R., Escribano, L., George, T. I., Kluijn-Nelemans, H. C., Ustun, C., Triggiani, et al
2020; 10 (23): 10743–68
 - **Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions.** *The Journal of allergy and clinical immunology*
Valent, P. n., Akin, C. n., Bonadonna, P. n., Brockow, K. n., Niedoszytko, M. n., Nedoszytko, B. n., Butterfield, J. H., Alvarez-Twose, I. n., Sotlar, K. n., Schwaab, J. n., Jawhar, M. n., Reiter, A. n., Castells, et al
2020
 - **Clinical Features and Survival of Patients with Indolent Systemic Mastocytosis defined by the Updated WHO Classification.** *Allergy*
Trizuljak, J. n., Sperr, W. R., Nekvindová, L. n., Oude Elberink, H. n., Gleixner, K. V., Gorska, A. n., Lange, M. n., Hartmann, K. n., Illerhaus, A. n., Bonifacio, M. n., Perkins, C. n., Elena, C. n., Malcovati, et al
2020
 - **New Developments in Diagnosis, Prognostication, and Treatment of Advanced Systemic Mastocytosis.** *Blood*
Reiter, A. n., George, T. I., Gotlib, J. R.
2020
 - **New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.** *Leukemia & lymphoma*
Arock, M., Sotlar, K., Gotlib, J., Sperr, W. R., Hartmann, K., Schwartz, L. B., Akin, C., Horny, H., Valent, P.
2019: 1–9
 - **Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.** *Leukemia*
Kluijn-Nelemans, H. C., Reiter, A., Illerhaus, A., van Anrooij, B., Hartmann, K., Span, L. F., Gorska, A., Niedoszytko, M., Lange, M., Scaffidi, L., Zanotti, R., Bonadonna, P., Perkins, et al
2019
 - **International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.** *The Lancet. Haematology*
Sperr, W. R., Kundi, M., Alvarez-Twose, I., van Anrooij, B., Oude Elberink, J. N., Gorska, A., Niedoszytko, M., Gleixner, K. V., Hadzijusufovic, E., Zanotti, R., Bonadonna, P., Bonifacio, M., Perkins, et al
2019
 - **Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study of the MYSEC group.** *American journal of hematology*
Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, et al
2019
 - **A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.** *Blood advances*
Gotlib, J., Baird, J. H., George, T. I., Langford, C., Reyes, I., Abuel, J., Perkins, C., Schroeder, K., Bose, P., Verstovsek, S.
2019; 3 (15): 2264–71
 - **Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.** *Blood*
Zhang, H., Wilmot, B., Bottomly, D., Dao, K. T., Stevens, E., Eide, C. A., Khanna, V., Rofeltly, A., Savage, S., Reister-Schultz, A., Long, N., White, L., Carlos, et al
2019
 - **MYC regulates the HIF-2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells.** *Cancer research*

- Das, B., Pal, B., Bhuyan, R., Li, H., Sarma, A., Gayan, S., Talukdar, J., Sandhya, S., Bhuyan, S., Gogoi, G., Gouw, A. M., Baishya, D., Gotlib, et al
2019
- **Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist** *INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY*
Li, P., Shahmarvand, N., Lynch, D., Gotlib, J. R., Merker, J. D., Zehnder, J. L., George, T., Ohgami, R. S.
2019; 41 (3): 345–52
 - **Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms.** *Hematological oncology*
Mughal, T. I., Pemmaraju, N., Radich, J. P., Deininger, M. W., Kucine, N., Kiladjan, J., Bose, P., Gotlib, J., Valent, P., Chen, C., Barbui, T., Rampal, R., Verstovsek, et al
2019
 - **Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis** *LEUKEMIA & LYMPHOMA*
Menghrajani, K., Boonstra, P. S., Mercer, J. A., Perkins, C., Gowin, K. L., Weber, A. A., Mesa, R., Gotlib, J. R., Wang, L., Singer, J. W., Talpaz, M.
2019; 60 (4): 1036–42
 - **TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis**
Williams, M., George, T., Tripp, S., Deininger, M., Gotlib, J., Hartmann, K.
NATURE PUBLISHING GROUP.2019
 - **TIM3 and Galectin-9 are Novel Therapeutic Targets for Mastocytosis**
Williams, M., George, T., Tripp, S., Deininger, M., Gotlib, J., Hartmann, K.
NATURE PUBLISHING GROUP.2019
 - **Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.** *International journal of laboratory hematology*
Li, P., Shahmarvand, N., Lynch, D., Gotlib, J. R., Merker, J. D., Zehnder, J. L., George, T. I., Ohgami, R. S.
2019
 - **Proposed Diagnostic Algorithm for Patients With Suspected Mast Cell Activation Syndrome.** *The journal of allergy and clinical immunology. In practice*
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., Nedoszytko, B., Siebenhaar, F., Sperr, W. R., Oude Elberink, J. N., Butterfield, J. H., Alvarez-Twose, I., Sotlar, et al
2019
 - **Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.** *Cancer medicine*
Mora, B. n., Rumi, E. n., Guglielmelli, P. n., Barraco, D. n., Maffioli, M. n., Rambaldi, A. n., Caramella, M. n., Komrokji, R. n., Gotlib, J. n., Kiladjan, J. J., Cervantes, F. n., Devos, T. n., Palandri, et al
2019
 - **MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Jawhar, M. n., Schwaab, J. n., Álvarez-Twose, I. n., Shoumariyeh, K. n., Naumann, N. n., Lübke, J. n., Perkins, C. n., Muñoz-González, J. I., Meggendorfer, M. n., Kennedy, V. n., Metzgeroth, G. n., Fabarius, A. n., Pfeifer, et al
2019: JCO1900640
 - **Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Dao, K. T., Gotlib, J. n., Deininger, M. M., Oh, S. T., Cortes, J. E., Collins, R. H., Winton, E. F., Parker, D. R., Lee, H. n., Reister, A. n., Schultz, n. n., Savage, S. n., Stevens, et al
2019: JCO1900895
 - **A Kindred with a β -Globin Base Substitution [β 89(F5)Ser→Arg (AGT>AGG)]; HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt.** *Hemoglobin*
Shomali, W. n., Brar, R. n., Arekapudi, S. R., Gotlib, J. R.
2019: 1–4
 - **World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.** *American journal of hematology*

- Shomali, W. n., Gotlib, J. n.
2019
- **Systemic Mastocytosis, Version 2.2019** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Gotlib, J., Gerds, A. T., Bose, P., Castells, M. C., Deininger, M. W., Gojo, I., Gundabolu, K., Hobbs, G., Jamieson, C., McMahon, B., Mohan, S. R., Oehler, V., Oh, et al
2018; 16 (12): 1500–1537
 - **The new tool "KIT" in advanced systemic mastocytosis.** *Hematology. American Society of Hematology. Education Program*
Shomali, W., Gotlib, J.
2018; 2018 (1): 127–36
 - **Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells**
Chae, H., Murphy, L. C., Donato, M., Lee, A. G., Sweet-Cordero, E., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Huang, M., Sumarsono, et al
AMER SOC HEMATOLOGY.2018
 - **PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study**
Verstovsek, S., Hasserjian, R. P., Pozdnyakova, O., Veletic, I., Mesa, R. A., Foltz, L., Mascarenhas, J., Ritchie, E. K., Palmer, J., Silver, R. T., Kremyanskaya, M., van den Blink, B., Gupta, et al
AMER SOC HEMATOLOGY.2018
 - **Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)**
Verstovsek, S., Vannucchi, A. M., Rambaldi, A., Gotlib, J. R., Mead, A. J., Hochhaus, A., Kiladjian, J., Hernandez Boluda, J., Asatiani, E., Lihou, C., Zhen, H., Reiter, A.
AMER SOC HEMATOLOGY.2018
 - **Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM)**
Gotlib, J. R., Radia, D., DeAngelo, D. J., Bose, P., Drummond, M. W., Hexner, E. O., Robinson, W. A., Conlan, M. G., Oren, R. G., Shi, H., Deininger, M. W.
AMER SOC HEMATOLOGY.2018
 - **Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia**
Dao, K., Collins, R. H., Cortes, J. E., Deininger, M. W., Druker, B. J., Gotlib, J. R., Macey, T., Oh, S. T., Tyner, J. W., Winton, E. F.
AMER SOC HEMATOLOGY.2018
 - **Comprehensive Cytokine Profiling of Patients with Advanced Systemic Mastocytosis Treated with Midostaurin**
Ediriwickrema, A., DeAngelo, D. J., George, T. I., Rosenberg-Hasson, Y., Perkins, C., Langford, C., Gotlib, J. R.
AMER SOC HEMATOLOGY.2018
 - **Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients**
Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R. S., Gotlib, J. R., Kiladjian, J., Cervantes, F., Devos, T., Palandri, et al
AMER SOC HEMATOLOGY.2018
 - **Impact of somatic and germline mutations on the outcome of systemic mastocytosis.** *Blood advances*
Munoz-Gonzalez, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Hou, Y., Henriques, A., Roskin, K. M., Sanchez-Munoz, L., Tsai, A. G., Caldas, C., Matito, A., Sanchez-Gallego, et al
2018; 2 (21): 2814–28
 - **The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives.** *The journal of allergy and clinical immunology. In practice*
Valent, P., Oude Elberink, J. N., Gorska, A., Lange, M., Zanotti, R., van Anrooij, B., Bonifacio, M., Bonadonna, P., Gleixner, K. V., Hadzijusufovic, E., Perkins, C., Hartmann, K., Illerhaus, et al
2018
 - **A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis** *BLOOD*
Masarova, L., Verstovsek, S., Hidalgo-Lopez, J. E., Pemmaraju, N., Bose, P., Estrov, Z., Jabbour, E. J., Ravandi-Kashani, F., Takahashi, K., Cortes, J. E., Ning, J., Ohanian, M., Alvarado, et al

2018; 132 (16): 1664–74

- **Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project** *BLOOD CANCER JOURNAL*
Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J., Cervantes, F., Devos, T., Palandri, et al
2018; 8
- **Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.** *Blood cancer journal*
Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, et al
2018; 8 (10): 89
- **Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., Hobbs, G., Jagasia, M., Kantarjian, et al
2018; 16 (9): 1108–35
- **PLATELET TRANSCRIPTOMIC SIGNATURES IN MYELOPROLIFERATIVE NEOPLASMS**
Krishnan, A., Perkins, C., Gotlib, J., Zehnder, J.
WILEY.2018: E34
- **THE NUMBER AND TYPE OF MUTATIONS IN CANCER-LINKED GENES IS ASSOCIATED WITH OUTCOME OF SYSTEMIC MASTOCYTOSIS.**
Munoz-Gonzalez, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Henriques, A., Sanchez-Munoz, L., Matito, A., Caldas, C., Ignacio Sanchez-Gallego, J., Mayado, A., Dasilva-Freire, N., Gotlib, et al
WILEY.2018: 102
- **Core-binding factor acute myeloid leukemia with t(8;21) Risk factors and a novel scoring system (I-CBFit)** *CANCER MEDICINE*
Ustun, C., Morgan, E., Moodie, E. E. M., Pullarkat, S., Yeung, C., Broesby-Olsen, S., Ohgami, R., Kim, Y., Sperr, W., Vestergaard, H., Chen, D., Kluin, P. M., Dolan, et al
2018; 7 (9): 4447–55
- **Mast cell activation syndrome: Importance of consensus criteria and call for research** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., Butterfield, J. H., Reiter, A., Gotlib, J., Castells, M., Milner, J. D., Carter, M. C., Komarow, et al
2018; 142 (3): 1008-+
- **Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project** *HAEMATOLOGICA*
Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J., Cervantes, F., Devos, T., Palandri, et al
2018; 103 (9): E392–E394
- **Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.** *Current hematologic malignancy reports*
Baird, J. H., Gotlib, J.
2018
- **Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells** *BLOOD ADVANCES*
Yun, H., Felices, M., Vallera, D. A., Hinderlie, P., Cooley, S., Arock, M., Gotlib, J., Ustun, C., Miller, J. S.
2018; 2 (13): 1580–84
- **Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia** *LEUKEMIA RESEARCH*
Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J., Cervantes, F., Devos, T., Palandri, et al
2018; 69: 100–102

- **Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Ma, V. T., Boonstra, P. S., Menghrajani, K., Perkins, C., Gowin, K. L., Mesa, R. A., Gotlib, J. R., Talpaz, M.
2018; 18 (5): E201–E210
- **Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial** *JAMA ONCOLOGY*
Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., Daly, R., Al-Fayoumi, S., Callahan, et al
2018; 4 (5): 652–59
- **Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms** *LEUKEMIA RESEARCH*
Mughal, T. I., Gotlib, J., Mesa, R., Koschmieder, S., Khoury, H., Cortes, J. E., Barbui, T., Hehlmann, R., Mauro, M., Saussele, S., Radich, J. P., Van Etten, R. A., Saglio, et al
2018; 67: 67–74
- **Trispecific Killer Engager CD16xIL15xCD33 Enhances Alloreactivity of NK Cells Against Aberrant Mast Cells of Patients with Systemic Mastocytosis**
Yun, H., Felices, M., Vallera, D. A., Cooley, S., Gotlib, J. R., Ustun, C., Miller, J. S.
ELSEVIER SCIENCE INC.2018: S148–S149
- **The Significance of Dim Cytoplasmic CD3 Expression in Acute Myeloid Leukemia: A Long-Term Retrospective Study Identifies an Association with Acute Promyelocytic Leukemia with FLT3-ITD Mutations**
Kumar, J., Nagy, A., Lacayo, N., Gotlib, J., Zehnder, J. L., Ohgami, R.
NATURE PUBLISHING GROUP.2018: 529
- **Myelophthitic marrow involved by breast cancer and acute myeloid leukemia** *BLOOD*
Shomali, W., Gotlib, J.
2018; 131 (9): 1036
- **Variability of PD-L1 expression in mastocytosis** *BLOOD ADVANCES*
Hatch, E. W., Geeze, M., Martin, C., Salama, M. E., Hartmann, K., Eisenwort, G., Blatt, K., Valent, P., Gotlib, J., Lee, J., Chen, L., Ward, H. H., Lidke, et al
2018; 2 (3): 189–99
- **SOHO State-of-the-Art Update and Next Questions: MPN** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Bose, P., Gotlib, J., Harrison, C. N., Verstovsek, S.
2018; 18 (1): 1–12
- **A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.** *International journal of hematology*
Dinner, S. n., Dunn, T. J., Price, E. n., Coutré, S. E., Gotlib, J. n., Berube, C. n., Kaufman, G. P., Medeiros, B. C., Liedtke, M. n.
2018
- **Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal** *EBIOMEDICINE*
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., Gotlib, J., Haferlach, T., Hoermann, G., Hermine, O., Jaeger, U., Kenner, L., Kreipe, et al
2017; 26: 17–24
- **Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal.** *EBioMedicine*
Valent, P., Akin, C., Arock, M., Bock, C., George, T. I., Galli, S. J., Gotlib, J., Haferlach, T., Hoermann, G., Hermine, O., Jäger, U., Kenner, L., Kreipe, et al
2017; 26: 17-24
- **World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J.
2017; 92 (11): 1243–59
- **Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in *Caenorhabditis elegans* and *Homo sapiens*.** *G3 (Bethesda, Md.)*

- Shoura, M. J., Gabdank, I., Hansen, L., Merker, J., Gotlib, J., Levene, S. D., Fire, A. Z.
2017; 7 (10): 3295-3303
- **A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia** *CANCER GENETICS*
Chung, A., Hou, Y., Ohgami, R. S., Von Gehr, A., Fisk, D. G., Roskin, K. M., Li, X., Gojenola, L., Bangs, C. D., Arber, D. A., Fire, A. Z., Cherry, A. M., Zehnder, et al
2017; 216: 10–15
 - **NCCN Guidelines (R) Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., McMahon, B., Mohan, S. R., Oh, et al
2017; 15 (10): 1193–1207
 - **Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia** *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*
Dao, K. T., Tyner, J. W., Gotlib, J.
2017; 12 (5): 432–41
 - **Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses** *JOURNAL OF HEMATOLOGY & ONCOLOGY*
Verstovsek, S., Gotlib, J., Mesa, R. A., Vannucchi, A. M., Kiladjian, J., Cervantes, F., Harrison, C. N., Paquette, R., Sun, W., Naim, A., Langmuir, P., Dong, T., Gopalakrishna, et al
2017; 10: 156
 - **SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Mesa, R. A., Kiladjian, J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E. F., Deng, W., Dubowy, R. L., Maltzman, J. D., Cervantes, et al
2017: JCO2017734418
 - **Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Gotlib, J.
2017; 31 (4): 643+
 - **A molecular roadmap for midostaurin in mastocytosis** *BLOOD*
Gotlib, J.
2017; 130 (2): 98–100
 - **Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Ustun, C., Williams, S., Skendzel, S., Kodal, B., Arock, M., Gotlib, J., Vallera, D. A., Cooley, S., Felices, M., Weisdorf, D., Miller, J.
2017; 92 (5): E66–E68
 - **Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.** *Cancer research*
Valent, P., Akin, C., Hartmann, K., Nilsson, G., Reiter, A., Hermine, O., Sotlar, K., Sperr, W. R., Escribano, L., George, T. I., Kluin-Nelemans, H. C., Ustun, C., Triggiani, et al
2017
 - **Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.** *Journal of hematology & oncology*
Verstovsek, S., Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, et al
2017; 10 (1): 55-?
 - **A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.** *British journal of haematology*
Verstovsek, S., Savona, M. R., Mesa, R. A., Dong, H., Maltzman, J. D., Sharma, S., Silverman, J., Oh, S. T., Gotlib, J.
2017
 - **How I treat atypical chronic myeloid leukemia** *BLOOD*

- Gotlib, J.
2017; 129 (7): 838-845
- **Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.** *Leukemia*
Valent, P., Sotlar, K., Blatt, K., Hartmann, K., Reiter, A., Sadovnik, I., Sperr, W. R., Bettelheim, P., Akin, C., Bauer, K., George, T. I., Hadzijušufovic, E., Wolf, et al
2017
 - **Myeloid neoplasms with eosinophilia** *BLOOD*
Reiter, A., Gotlib, J.
2017; 129 (6): 704-714
 - **The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia**
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 358A–359A
 - **Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease**
Davion, S., Wang, S., Silva, O., Sadigh, S., Arber, D. A., Bagg, A., Gotlib, J., George, T.
NATURE PUBLISHING GROUP.2017: 345A
 - **Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes**
Sojitra, P., Hatch, E. W., Martin, C., Gotlib, J. R., Ward, H., Lidke, D. S., George, T.
NATURE PUBLISHING GROUP.2017: 378A
 - **Mast Cell Leukemia (MCL); Clinicopathologic Features of a Rare Disease**
Davion, S., Wang, S., Silva, O., Sadigh, S., Arber, D. A., Bagg, A., Gotlib, J., George, T.
NATURE PUBLISHING GROUP.2017: 345A
 - **Quantitative Analysis of Ki67 in Mastocytosis Distinguishes Mast Cell Leukemia from Other Subtypes**
Sojitra, P., Hatch, E. W., Martin, C., Gotlib, J. R., Ward, H., Lidke, D. S., George, T.
NATURE PUBLISHING GROUP.2017: 378A
 - **The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings**
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
 - **A Detailed Multi parameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study**
Segal, J., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
 - **Detailed Multiparameter Flow Cytometry Study of 365 Cases of B-Lymphoblastic Leukemia with Subtyping According to the 2016 WHO: A Single Institutional Study**
Segal, J., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
 - **The Significance of Morphologic Dysplasia in 432 Cases of Acute Lymphoblastic Leukemia and Acute Leukemia of Ambiguous Lineage: Correlation with Cytogenetic, Immunophenotypic, and Molecular Findings**
Segal, J., Dahl, G., Lacayo, N., Gotlib, J., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 376A
 - **The Significance of CD56 Expression and the RAM Immunophenotype, a Recurrent Immunophenotype Seen in Children, in Adult Acute Myeloid Leukemia**
Lazzareschi, D., Cherry, A., Zehnder, J., Gotlib, J., Arber, D. A., Lacayo, N., Ohgami, R.
NATURE PUBLISHING GROUP.2017: 358A–359A
 - **The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia.** *International journal of laboratory hematology*
Alcasid, M., Ma, L., Gotlib, J. R., Arber, D. A., Ohgami, R. S.
2017

- **Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in *Caenorhabditis elegans* and *Homo sapiens*** *G3: GENES, GENOMES, GENETICS*
Shoura, M., Gabdank, I., Merker, J., Gotlib, J., Levene, S., Fire, A.
2017; 7: 3295-3303
- **Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)**
Sperr, W. R., Kundi, M., Elberink, H., van Anrooij, B., Gleixner, K. V., Hadzijusufovic, E., Gorska, A., Lange, M., Rabenhorst, A., Merante, S., Elena, C., Fortina, A., Fontana, et al
AMER SOC HEMATOLOGY.2016
- **NCCN Guidelines (R) Insights Chronic Myeloid Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pallera, A., Altman, J. K., Berman, E., Abboud, C. N., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., Hagelstrom, R. T., Hobbs, G., Jagasia, M., Kantarjian, H. M., Kropf, et al
2016; 14 (12): 1505-1512
- **Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network*
Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., Klisovic, R. B., Kropf, P., Mohan, S. R., Oh, et al
2016; 14 (12): 1572-1611
- **Myeloproliferative Neoplasms, Version 2.2017** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Mesa, R., Jamieson, C., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., Klisovic, R. B., Kropf, P., Mohan, S. R., Oh, et al
2016; 14 (12): 1572-1611
- **Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.** *Haematologica*
Ustun, C., Arock, M., Kluin-Nelemans, H. C., Reiter, A., Sperr, W. R., George, T., Horny, H., Hartmann, K., Sotlar, K., Damaj, G., Hermine, O., Verstovsek, S., Metcalfe, et al
2016; 101 (10): 1133-1143
- **Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.** *Blood*
Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. M., Zhang, H., Gojenola, L., Zehnder, et al
2016; 128 (8): 1121-1128
- **Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.** *Leukemia*
Alvarez-Twose, I., Martínez-Barranco, P., Gotlib, J., García-Montero, A., Morgado, J. M., Jara-Acevedo, M., Merker, J. D., Peñalver, F. J., Matito, A., Hou, Y., Sánchez-Muñoz, L., Mayado, A., Mollejo, et al
2016; 30 (8): 1753-1756
- **Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Ustun, C., Gotlib, J., Popat, U., Artz, A., Litzow, M., Reiter, A., Nakamura, R., Kluin-Nelemans, H. C., Verstovsek, S., Gajewski, J., Perales, M., George, T., Shore, et al
2016; 22 (8): 1348-56
- **Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis** *NEW ENGLAND JOURNAL OF MEDICINE*
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E., Mauro, M. J., Sternberg, D. W., Villeneuve, M., Labeled, A. H., Stanek, et al
2016; 374 (26): 2530-2541
- **A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.** *British journal of haematology*
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., Berube, C., Medeiros, B. C., Liedtke, M.
2016; 173 (2): 253-259
- **Age-related mutations and chronic myelomonocytic leukemia** *LEUKEMIA*
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Zabriskie, M. S., Yan, D., Pomicter, A. D., Reynolds, K. R., Eiring, A. M., Kronenberg, Z., Sherman, R. L., Tyner, J. W., Dalley, et al

2016; 30 (4): 906-913

- **Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.** *Leukemia*
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., Bangs, C. D., Cherry, A. M., Arai, S., Arber, D. A., Zehnder, J. L., Gotlib, J.
2016; 30 (4): 947-950
- **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome** *LEUKEMIA & LYMPHOMA*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
- **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.** *Leukemia & lymphoma*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
- **The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.** *Clinical cancer research*
Maxson, J. E., Luty, S. B., Macmaniman, J. D., Paik, J. C., Gotlib, J., Greenberg, P., Bahamadi, S., Savage, S. L., Abel, M. L., Eide, C. A., Loriaux, M. M., Stevens, E. A., Tyner, et al
2016; 22 (3): 757-764
- **PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis**
Geeze, M., Hatch, E., Martin, C., Perkins, S. L., Hartmann, K., Valent, P., Gotlib, J., Lidke, D., George, T. I.
NATURE PUBLISHING GROUP.2016: 346A
- **PD-1/PD-L1 Are Novel Therapeutic Targets for Mastocytosis**
Geeze, M., Hatch, E., Martin, C., Perkins, S. L., Hartmann, K., Valent, P., Gotlib, J., Lidke, D., George, T. I.
NATURE PUBLISHING GROUP.2016: 346A
- **Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
Hartmann, K., Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., Matito, A., Broesby-Olsen, S., Siebenhaar, F., Lange, M., Niedoszytko, M., Castells, M., Oude Elberink, et al
2016; 137 (1): 35-45
- **Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.** *The Journal of allergy and clinical immunology*
Hartmann, K., Escribano, L., Grattan, C., Brockow, K., Carter, M. C., Alvarez-Twose, I., Matito, A., Broesby-Olsen, S., Siebenhaar, F., Lange, M., Niedoszytko, M., Castells, M., Oude Elberink, et al
2016; 137 (1): 35-45
- **PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks**
Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J. O., Ritchie, E. K., Hoffman, R., Silver, R. T., Kremyanskaya, M., Pozdnyakova, O., Hasserjian, R. P., Trehu, E., Salama, et al
AMER SOC HEMATOLOGY.2015
- **A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis**
Verstovsek, S., Savona, M. R., Mesa, R. A., Oh, S., Dong, H., Thai, D., Gotlib, J.
AMER SOC HEMATOLOGY.2015
- **Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis** *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*
Gotlib, J.
2015; 10 (4): 351-361

- **World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J.
2015; 90 (11): 1078-89
- **Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis** *JOURNAL OF TRANSLATIONAL MEDICINE*
Jamieson, C., Hasserjian, R., Gotlib, J., Cortes, J., Stone, R., Talpaz, M., Thiele, J., Rodig, S., Pozdnyakova, O.
2015; 13
- **A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis** *HAEMATOLOGICA*
Vannucchi, A. M., Kantarjian, H. M., Kiladjan, J., Gotlib, J., Cervantes, F., Mesa, R. A., Sarris, N. J., Peng, W., Sandor, V., Gopalakrishna, P., Hmissi, A., Stalbovskaya, V., Gupta, et al
2015; 100 (9): 1139-1145
- **Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis** *LEUKEMIA & LYMPHOMA*
Sasaki, K., Gotlib, J. R., Mesa, R. A., Newberry, K. J., Ravandi, F., Cortes, J. E., Kelly, P., Kutok, J. L., Kantarjian, H. M., Verstovsek, S.
2015; 56 (7): 2092-2097
- **KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis** *LEUKEMIA*
Arock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., Kristensen, T. K., Kluin-Nelemans, H. C., Hermine, O., Dubreuil, P., Sperr, W. R., Hartmann, K., Gotlib, et al
2015; 29 (6): 1223-1232
- **To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors**
Menghrajani, K., Boonstra, P. S., Weber, A., Perkins, C., Gowin, K., Huong Nguyen, Mesa, R., Gotlib, J. R., Talpaz, M.
CIG MEDIA GROUP, LP.2015: S236
- **Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations** *MODERN PATHOLOGY*
Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., Arber, D. A.
2015; 28 (5): 706-714
- **Mast Cells in Systemic Mastocytosis Have Distinctly Brighter CD45 Expression by Flow Cytometry** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*
Chisholm, K. M., Merker, J. D., Gotlib, J. R., Gitana, G., Lefterova, M., Zehnder, J. L., George, T. I., Arber, D. A., Ohgami, R. S.
2015; 143 (4): 527-534
- **Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.** *Haematologica*
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
2015; 100 (4): 479-488
- **Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Mesa, R. A., Verstovsek, S., Gupta, V., Mascarenhas, J. O., Atallah, E., Burn, T., Sun, W., Sandor, V., Gotlib, J.
2015; 15 (4): 214-221
- **Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I** *HAEMATOLOGICA*
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
2015; 100 (4): 482-491
- **Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Stein, B. L., Gotlib, J., Arcasoy, M., Nguyen, M. H., Shah, N., Moliterno, A., Jamieson, C., Pollyea, D. A., Scott, B., Wadleigh, M., Levine, R., Komrokji, R., Klisovic, et al
2015; 13 (4): 424-434

- **Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance** *NATURE MEDICINE*
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S., Kim, S. S., Liu, H., Tivey, T., Christie, et al
2015; 21 (1): 71-75
- **A New Prognostic Model for Response in Myelofibrosis Patients Treated with JAK2 Inhibitors: A Study from Three US Academic Centers**
Kamal, M., Boonstra, P. S., Weber, A. A., Perkins, C., Gowin, K. L., Huong (Marie) Nguyen, Mesa, R., Gotlib, J. R., Talpaz, M.
AMER SOC HEMATOLOGY.2014
- **GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition**
Yoda, A., Adelmant, G., Tamburini, J., Chapuy, B., Shindoh, N., Yoda, Y., Weigert, O., Kopp, N., Wu, S., Kim, S. S., Liu, H., Tivey, T., Christie, et al
AMER SOC HEMATOLOGY.2014
- **Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results**
Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J. O., Ritchie, E. K., Hoffman, R., Silver, R. T., Kremyanskaya, M., Pozdnyakova, O., Hasserjian, R. P., Trehu, E., Kantarjian, et al
AMER SOC HEMATOLOGY.2014
- **Next Generation Sequencing to Delineate the Mutational Landscape of Chronic Myelomonocytic Leukemia (CMML): Novel Disease Genes and Correlations with Survival**
Mason, C. C., Khorashad, J. S., Tantravahi, S. K., Kelley, T. W., Pomicter, A. D., Iovino, A. J., Reynolds, K. R., Eiring, A. M., Zabriskie, M. S., Kronenberg, Z., Tyner, J. W., Dalley, B., Dao, et al
AMER SOC HEMATOLOGY.2014
- **Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial**
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F., Hexner, E. O., Mauro, M., Sternberg, D., Villeneuve, M., Emery-Salbert, F., Stanek, et al
AMER SOC HEMATOLOGY.2014
- **A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocytopenia: The Mysec Prognostic Model (MYSEC-PM)**
Passamonti, F., Alessandro, V., Domenica, C., Alessandro, R., Enrica, M., Jacques, K., Komrokji, R. S., Maffioli, M., Gotlib, J., Francisco, C., Devos, T., Silver, R. T., Guglielmelli, et al
AMER SOC HEMATOLOGY.2014
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA RESEARCH*
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., Patel, S., Medeiros, B.
2014; 38 (12): 1441-1445
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.** *Leukemia research*
Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., Patel, S., Medeiros, B.
2014; 38 (12): 1441-1445
- **Chronic Myelogenous Leukemia, Version 1.2015 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P., DeAngelo, D. J., Deininger, M., Devine, S., Fathi, A. T., Gotlib, J., Jagasia, et al
2014; 12 (11): 1590-1609
- **Chronic myelogenous leukemia, version 1.2015.** *Journal of the National Comprehensive Cancer Network*
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P., DeAngelo, D. J., Deininger, M., Devine, S., Fathi, A. T., Gotlib, J., Jagasia, et al
2014; 12 (11): 1590-1610
- **The serum tryptase test: an emerging robust biomarker in clinical hematology** *EXPERT REVIEW OF HEMATOLOGY*
Valent, P., Sperr, W. R., Sotlar, K., Reiter, A., Akin, C., Gotlib, J., Horny, H., Arock, M.
2014; 7 (5): 683-690
- **Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis** *ALLERGY*

- Valent, P., Escribano, L., Broesby-Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., NEDOSZYTKO, B., Elberink, J. N., Kristensen, T., Butterfield, J. H., Triggiani, M., Alvarez-Twose, et al
2014; 69 (10): 1267-1274
- **Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Gupta, V., Gotlib, J., Radich, J. P., Kroeger, N. M., Rondelli, D., Verstovsek, S., Deeg, H. J.
2014; 20 (9): 1274-1281
 - **Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal** *ANNALS OF ONCOLOGY*
Valent, P., Sotlar, K., Sperr, W. R., Escribano, L., Yavuz, S., Reiter, A., George, T. I., Kluijn-Nelemans, H. C., Hermine, O., Butterfield, J. H., Hagglund, H., Ustun, C., Hornick, et al
2014; 25 (9): 1691-1700
 - **Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings.** *American journal of clinical pathology*
Weinberg, O. K., Ohgami, R. S., Ma, L., Seo, K., Ren, L., Gotlib, J. R., Seetharam, M., Cherry, A., Arber, D. A.
2014; 142 (2): 190-195
 - **Altered translation of GATA1 in Diamond-Blackfan anemia** *NATURE MEDICINE*
Ludwig, L. S., Gazda, H. T., Eng, J. C., Eichhorn, S. W., Thiru, P., Ghazvinian, R., George, T. I., Gotlib, J. R., Beggs, A. H., Sieff, C. A., Lodish, H. F., Lander, E. S., Sankaran, et al
2014; 20 (7): 748-753
 - **Hereditary erythrocytosis, thrombocytosis and neutrophilia** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Hong, W., Gotlib, J.
2014; 27 (2): 95-106
 - **A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.**
Sasaki, K., Gotlib, J. R., Mesa, R. A., Ravandi, F., Cortes, J. E., Kelly, P., Kutok, J., Kantarjian, H. M., Verstovsek, S.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.**
Verstovsek, S., Mesa, R. A., Foltz, L. M., Gupta, V., Mascarenhas, J., Ritchie, E. K., Hoffman, R., Silver, R. T., Hong, W., Kremyanskaya, M., Trehu, E. G., Kantarjian, H. M., Gotlib, et al
AMER SOC CLINICAL ONCOLOGY.2014
 - **Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study.** *Hematology reports*
Chan, S. M., Chadwick, J., Young, D. L., Holmes, E., Gotlib, J.
2014; 6 (2): 5466-?
 - **Two faces of ET: CALR and JAK2** *BLOOD*
Chao, M. P., Gotlib, J.
2014; 123 (10): 1438-40
 - **CME Information: World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J.
2014; 89 (3): 325-337
 - **Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies** *HAEMATOLOGICA*
Mesa, R. A., Kiladjian, J., Verstovsek, S., Al-Ali, H. K., Gotlib, J., Gisslinger, H., Levy, R., Siulnik, A., Gupta, V., Khan, M., DiPersio, J. F., McQuitty, M., Catalano, et al
2014; 99 (2): 292-298
 - **Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes** *ONCOTARGETS AND THERAPY*
Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., Sun, W., Sarlis, N. J., Sandor, V., Levy, R. S., Kantarjian, H. M., Mesa, R. A.

2014; 7: 13-21

- **Eosinophilic myeloproliferative disorders** *CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE*
Gotlib, J.
edited by Abutalib, S. A., Markman, M.
2014: 167-75
- **JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*
Gotlib, J.
2013: 529-537
- **Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I** *HAEMATOLOGICA*
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
2013; 98 (12): 1865-1871
- **Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes.** *Haematologica*
Merker, J. D., Roskin, K. M., Ng, D., Pan, C., Fisk, D. G., King, J. J., Hoh, R., Stadler, M., Okumoto, L. M., Abidi, P., Hewitt, R., Jones, C. D., Gojenola, et al
2013; 98 (11): 1689-1696
- **Chronic Myelogenous Leukemia, Version 1.2014.** *Journal of the National Comprehensive Cancer Network*
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., DeAngelo, D. J., Deininger, M., Devine, S., Fathi, A. T., Gotlib, J., Jagasia, M., Kropf, et al
2013; 11 (11): 1327-1340
- **Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
O'Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., DeAngelo, D. J., Deininger, M., Devine, S., Fathi, A. T., Gotlib, J., Jagasia, M., Kropf, et al
2013; 11 (11): 1327-1340
- **Hidden Mastocytosis in Acute Myeloid Leukemia With t(8;21)(q22;q22).** *American journal of clinical pathology*
Johnson, R. C., Savage, N. M., Chiang, T., Gotlib, J. R., Cherry, A. M., Arber, D. A., George, T. I.
2013; 140 (4): 525-535
- **Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review** *INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY*
Savage, N., George, T. I., Gotlib, J.
2013; 35 (5): 491-500
- **Practical management of patients with myelofibrosis receiving ruxolitinib** *EXPERT REVIEW OF HEMATOLOGY*
Harrison, C., Mesa, R., Ross, D., Mead, A., Keohane, C., Gotlib, J., Verstovsek, S.
2013; 6 (5): 511-523
- **The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.** *Blood*
Gotlib, J., Maxson, J. E., George, T. I., Tyner, J. W.
2013; 122 (10): 1707-1711
- **Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report** *BLOOD*
Tefferi, A., Cervantes, F., Mesa, R., Passamonti, F., Verstovsek, S., Vannucchi, A. M., Gotlib, J., Dupriez, B., Pardanani, A., Harrison, C., Hoffman, R., Gisslinger, H., Kroeger, et al
2013; 122 (8): 1395-1398
- **Editorial. Therapeutic advances in hematology**
Gotlib, J.
2013; 4 (4): 235-236

- **Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML** *NEW ENGLAND JOURNAL OF MEDICINE*
Maxson, J. E., Gotlib, J., Pollyea, D. A., Fleischman, A. G., Agarwal, A., Eide, C. A., Bottomly, D., Wilmot, B., McWeeney, S. K., Tognon, C. E., Pond, J. B., Collins, R. H., Goueli, et al
2013; 368 (19): 1781-1790
- **The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
2013; 161 (4): 508-516
- **Myeloid and lymphoid Neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges** *AMERICAN JOURNAL OF HEMATOLOGY*
Savage, N. M., Johnson, R. C., Gotlib, J., George, T. I.
2013; 88 (5): 427-430
- **Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial** *JOURNAL OF CLINICAL ONCOLOGY*
Mesa, R. A., Gotlib, J., Gupta, V., Catalano, J. V., Deininger, M. W., Shields, A. L., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Hare, T., Erickson-Viitanen, et al
2013; 31 (10): 1285-1292
- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al
2013; 98 (4): 591-596
- **International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis** *BLOOD*
Gotlib, J., Pardanani, A., Akin, C., Reiter, A., George, T., Hermine, O., Kluin-Nelemans, H., Hartmann, K., Sperr, W. R., Brockow, K., Schwartz, L. B., Orfao, A., DeAngelo, et al
2013; 121 (13): 2393-2401
- **A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition** *CELL STEM CELL*
Goff, D. J., Recart, A. C., Sadarangani, A., Chun, H., Barrett, C. L., Krajewska, M., Leu, H., Low-Marchelli, J., Ma, W., Shih, A. Y., Wei, J., Zhai, D., Geron, et al
2013; 12 (3): 316-328
- **Accessory splenules in autoimmune hemolytic anemia.** *American journal of hematology*
Logan, A., Berube, C., Gotlib, J.
2013; 88 (2): 156-?
- **A Detailed Flow Cytometry Analysis of the Immune System in Non-Leukemic Cells of Acute Myeloid Leukemia Demonstrates the Prognostic Significance of Lymphocyte Subsets** *102nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)*
Ohgami, R. S., Alcasid, M., Ren, L., Gotlib, J. R., Arber, D. A.
NATURE PUBLISHING GROUP.2013: 353A-354A
- **Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening** *CANCER RESEARCH*
Tyner, J. W., Yang, W. F., Bankhead, A., Fan, G., Fletcher, L. B., Bryant, J., Glover, J. M., Chang, B. H., Spurgeon, S. E., Fleming, W. H., Kovacs, T., Gotlib, J. R., Oh, et al
2013; 73 (1): 285-296
- **Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.** *OncoTargets and therapy*
Verstovsek, S., Gotlib, J., Gupta, V., Atallah, E., Mascarenhas, J., Quintas-Cardama, A., Sun, W., Sarlis, N. J., Sandor, V., Levy, R. S., Kantarjian, H. M., Mesa, R. A.
2013; 7: 13-21
- **ICON: Eosinophil Disorders.** *The World Allergy Organization journal*
Valent, P., Klion, A. D., Rosenwasser, L. J., Arock, M., Bochner, B. S., Butterfield, J. H., Gotlib, J., Haferlach, T., Hellmann, A., Horny, H., Leiferman, K. M., Metzgeroth, G., Matsumoto, et al

2012; 5 (12): 174-181

- **Next-generation sequencing in hematologic malignancies: what will be the dividends?** *Therapeutic advances in hematology*
Merker, J. D., Valouev, A., Gotlib, J.
2012; 3 (6): 333-339
- **Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Nguyen, H. (. , Hinds, D. A., Barnholt, K. E., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. A., Levine, R. L., Zehnder, J. L., Gotlib, J., Mesa, et al
AMER SOC HEMATOLOGY.2012
- **KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial**
Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F., Hexner, E., Mauro, M. J., Morariu, R., Squier, M., Villeneuve, M., Emery-Salbert, et al
AMER SOC HEMATOLOGY.2012
- **Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I**
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
AMER SOC HEMATOLOGY.2012
- **A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms**
Hinds, D. A., Barnholt, K. E., Zehnder, J. L., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. A., Huang (Marie) Nguyen, Levine, R. L., Mesa, R. A., Gotlib, J.
AMER SOC HEMATOLOGY.2012
- **Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis**
Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W., Wadleigh, M., Sirhan, S., Bavisotto, L. M., Kawashima, J., Kowalski, M., Tefferi, A.
AMER SOC HEMATOLOGY.2012
- **Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials**
Verstovsek, S., Kiladjian, J., Mesa, R. A., Vannucchi, A. M., Gotlib, J., Barosi, G., Kantarjian, H. M., Sirulnik, A., Peng, W., Sandor, V. A., Harrison, C. N.
AMER SOC HEMATOLOGY.2012
- **Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms**
Mesa, R. A., Gotlib, J., Kantarjian, H. M., Sun, W., Verstovsek, S.
AMER SOC HEMATOLOGY.2012
- **Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I**
Mesa, R. A., Verstovsek, S., Gupta, V., Mascarenhas, J., Atallah, E., Sun, W., Sandor, V. A., Gotlib, J.
AMER SOC HEMATOLOGY.2012
- **Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy**
Pollyea, D. A., Zehnder, J. L., Coutre, S., Gotlib, J., Gallegos, L., Greenberg, P., Zhang, B., Liedtke, M., Levine, R. L., Medeiros, B. C.
AMER SOC HEMATOLOGY.2012
- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study**
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Nguyen, H. (. , Anh Pham, A., Perkins, C., Linder, A., Fechter, L., Gotlib, J.
AMER SOC HEMATOLOGY.2012

- **Whole Genome Sequence Analysis of Primary Myelofibrosis.** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Merker, J. D., Roskin, K., Ng, D., Pan, C., Fisk, D. G., Jones, C. D., Gojenola, L., Clark, M. J., Zhang, B., Cherry, M., Snyder, M., Boyd, S. D., Zehnder, et al
AMER SOC HEMATOLOGY.2012
- **A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Leu, H. S., Goff, D. J., Low-Marchelli, J., Recart, A. C., Smith, K. M., Ma, W., Sadarangani, A., Shih, A. Y., Wei, J., Zhai, D., Gotlib, J., Minden, M. D., Martinelli, et al
AMER SOC HEMATOLOGY.2012
- **Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Barnholt, K. E., Hinds, D. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. A., Nguyen, H. (.), Levine, R. L., Mesa, R. A., Gotlib, J., Zehnder, et al
AMER SOC HEMATOLOGY.2012
- **DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups** *BRITISH JOURNAL OF HAEMATOLOGY*
Ohgami, R. S., Ma, L., Ren, L., Weinberg, O. K., Seetharam, M., Gotlib, J. R., Arber, D. A.
2012; 159 (2): 182-190
- **World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.** *American journal of hematology*
Gotlib, J.
2012; 87 (9): 903-914
- **Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
Valent, P., Klion, A. D., Horny, H., Roufosse, F., Gotlib, J., Weller, P. F., Hellmann, A., Metzgeroth, G., Leiferman, K. M., Arock, M., Butterfield, J. H., Sperr, W. R., Sotlar, et al
2012; 130 (3): 607-?
- **Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.**
Verstovsek, S., Mesa, R. A., Gotlib, J. R., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J., Arcasoy, et al
AMER SOC CLINICAL ONCOLOGY.2012
- **Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia** *LEUKEMIA*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., Bhattacharya, S., Zehnder, J., Liedtke, M., Gotlib, J. R., Coutre, S., Berube, C., Melnick, et al
2012; 26 (5): 893-901
- **Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post-ASH symposium** *AMERICAN JOURNAL OF HEMATOLOGY*
Abdel-Wahab, O., Pardananani, A., Bernard, O. A., Finazzi, G., Crispino, J. D., Gisslinger, H., Kralovics, R., Odenike, O., Bhalla, K., Gupta, V., Barosi, G., Gotlib, J., Guglielmelli, et al
2012; 87 (5): 562-568

- **Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders** *SEMINARS IN HEMATOLOGY*
Gotlib, J., Akin, C.
2012; 49 (2): 128-137
- **Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field** *EXPERT REVIEW OF HEMATOLOGY*
Valent, P., Gleich, G. J., Reiter, A., Roufosse, F., Weller, P. F., Hellmann, A., Metzgeroth, G., Leiferman, K. M., Arock, M., Sotlar, K., Butterfield, J. H., Cerny-Reiterer, S., Mayerhofer, et al
2012; 5 (2): 157-176
- **A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis** *NEW ENGLAND JOURNAL OF MEDICINE*
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
2012; 366 (9): 799-807
- **Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review** *AMERICAN JOURNAL OF HEMATOLOGY*
Ustun, C., Savage, N. M., Gotlib, J., Bhalla, K., Manaloor, E., George, T. I.
2012; 87 (2): 191-193
- **Loss of CD25 Expression in Advanced Systemic Mastocytosis Patients Treated with Midostaurin (PKC412)** *101st Annual Meeting of United-States-and-Canadian-Academy-of-Pathology (USCAP)*
Kunder, C. A., DeAngelo, D. J., Gotlib, J. R., Gitana, G., Atwater, S. K., George, T. I.
NATURE PUBLISHING GROUP.2012: 349A-349A
- **Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., Zehnder, J. L.
2012; 87 (1): 45-50
- **Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., Bhat, N. M., Teng, N. N., Coutre, S. E.
2012; 97 (1): 30-37
- **Treatment advances have not improved the early death rate in acute promyelocytic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., Medeiros, B. C.
2012; 97 (1): 133-136
- **Chronic Myelogenous Leukemia** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
O'Brien, S., Abboud, C. N., Akhtari, M., Altman, J., Berman, E., DeAngelo, D. J., Devine, S., Fathi, A. T., Gotlib, J., Jagasia, M., Moore, J. O., Pinilla-Ibarz, J., Radich, et al
2012; 10 (1): 64-110
- **Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., Bhat, N. M., Teng, N. N., Coutre, S. E.
2012; 97 (1): 30-37
- **A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia.** *Blood*
Zhang, B., Ng, D., Jones, C., Oh, S. T., Nolan, G. P., Salehi, S., Wong, W., Zehnder, J. L., Gotlib, J.
2011; 118 (26): 6988-6990
- **A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia** *BLOOD*
Ng, D., Jones, C., Oh, S. T., Nolan, G. P., Salehi, S., Wong, W., Zehnder, J. L., Gotlib, J.
2011; 118 (26): 6988-?
- **Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-1** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*

- Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, et al
AMER SOC HEMATOLOGY.2011: 128–29
- **Cycling Toward Leukemia Stem Cell Elimination With a Selective Sonic Hedgehog Antagonist**
Shih, A. Y., Schairer, A., Barrett, C. L., Geron, I., Recart, A., Goff, D., Prashad, S., Wu, J., Jiang, Q., Gotlib, J., Balaian, L., Minden, M. D., Leu, et al
AMER SOC HEMATOLOGY.2011: 1613
 - **Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF**
Mesa, R. A., Gotlib, J., Gupta, V., DiPersio, J. F., Catalano, J., Deininger, M. W., Shields, A., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Hare, et al
AMER SOC HEMATOLOGY.2011: 1642–43
 - **An Expanded Multicenter Phase I/II Study of CYT387, a JAK-1/2 Inhibitor for the Treatment of Myelofibrosis**
Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W., Wadleigh, M., Sirhan, S., Litzow, M. R., Hogan, W. J., Begna, K., Smith, G., Bavisotto, L. M., Kowalski, M., Tefferi, et al
AMER SOC HEMATOLOGY.2011: 1645
 - **SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Pardanani, A., Gotlib, J., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R., Gao, G., Zhang, J. (., Neumann, F., Tefferi, A.
AMER SOC HEMATOLOGY.2011: 1640–40
 - **BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Goff, D., Smith, K. M., Shih, A. Y., Court-Recart, A., Sadarangani, A., Geron, I., Chuang, R., Balaian, L., Wei, J., Kitada, S., Zhai, D., Gotlib, J., Minden, et al
AMER SOC HEMATOLOGY.2011: 1176–76
 - **Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors** *HEMATOLOGICAL ONCOLOGY*
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., Mitchell, B. S.
2011; 29 (3): 157-160
 - **KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib** *BLOOD*
Gleixner, K. V., Mayerhofer, M., Cerny-Reiterer, S., Hoermann, G., Rix, U., Bennett, K. L., Hadzijusufovic, E., Meyer, R. A., Pickl, W. F., Gotlib, J., Horny, H., Reiter, A., Mitterbauer-Hohendanner, et al
2011; 118 (7): 1885-1898
 - **World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.** *American journal of hematology*
Gotlib, J.
2011; 86 (8): 677-688
 - **World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J.
2011; 86 (8): 678-688
 - **Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis** *JOURNAL OF CLINICAL ONCOLOGY*
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., Tefferi, A.
2011; 29 (7): 789-796
 - **Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium** *BLOOD CANCER JOURNAL*
Tefferi, A., Abdel-Wahab, O., Cervantes, F., Crispino, J. D., Finazzi, G., Girodon, F., Gisslinger, H., Gotlib, J., Kiladjian, J., Levine, R. L., Licht, J. D., Mullally, A., Odenike, et al
2011; 1
 - **Eosinophilic Disorders: Differential Diagnosis and Management** *MYELOPROLIFERATIVE NEOPLASMS- BIOLOGY AND THERAPY*

- Gotlib, J.
edited by Verstovsek, S., Tefferi, A.
2011: 181–203
- **Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Zhang, M., Arber, D. A., Zehnder, J. L.
AMER SOC HEMATOLOGY.2010: 1357–58
 - **KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial**
Gotlib, J., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., Dutreix, C., Gross, S., Nikolova, Z., Graubert, T.
AMER SOC HEMATOLOGY.2010: 144
 - **Longer-Term Follow up with TG101348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly,, Disease-Related Symptoms, and JAK2V617F Allele Burden**
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Shorr, J., Gilliland, D., Tefferi, A.
AMER SOC HEMATOLOGY.2010: 205–6
 - **A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes**
Pollyea, D. A., Raval, A., Kusler, B., Gotlib, J. R., Alizadeh, A. A., Mitchell, B. S.
AMER SOC HEMATOLOGY.2010: 788
 - **Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Gotlib, J., Zhang, B., Jones, C. D., Riess, J., Wong, W. B., Simonds, E. F., Hale, M. B., Abidi, P., McClung, J., Nolan, G. P., Oh, S. T., Zehnder, J. L.
AMER SOC HEMATOLOGY.2010: 1272–72
 - **A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., Liedtke, M., Mitchell, B. S., Medeiros, B. C.
AMER SOC HEMATOLOGY.2010: 1347–47
 - **Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Oh, S. T., Zahn, J. M., Jones, C. D., Zhang, B., Loh, M. L., Kantarjian, H., Simonds, E. F., Bruggner, R. V., Abidi, P., Natsoulis, G., Bell, J., Buenrostro, J., Nolan, et al
AMER SOC HEMATOLOGY.2010: 143–44
 - **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.
2010; 85 (11): 877-881
 - **LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations** *LEUKEMIA*
Pardanani, A., Lasho, T., Finke, C., Oh, S. T., Gotlib, J., Tefferi, A.
2010; 24 (10): 1713-1718
 - **Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms** *BLOOD*
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., Gotlib, J.
2010; 116 (6): 988-992
 - **Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge** *AMERICAN JOURNAL OF HEMATOLOGY*
Arredondo, A. R., Gotlib, J., Shier, L., Medeiros, B., Wong, K., Cherry, A., Corless, C., Arber, D. A., Valent, P., George, T. I.
2010; 85 (8): 600-606
 - **JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms** *EXPERT REVIEW OF HEMATOLOGY*
Oh, S. T., Gotlib, J.

2010; 3 (3): 323-337

- **Eosinophilic myeloid disorders: new classification and novel therapeutic strategies** *CURRENT OPINION IN HEMATOLOGY*
Gotlib, J.
2010; 17 (2): 117-124
- **Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update** *MAYO CLINIC PROCEEDINGS*
Tefferi, A., Gotlib, J., Pardanani, A.
2010; 85 (2): 158-164
- **Design and Evaluation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-Type JAK2 Transcript Levels in the Clinical Laboratory** *JOURNAL OF MOLECULAR DIAGNOSTICS*
Merker, J. D., Jones, C. D., Oh, S. T., Schrijver, I., Gotlib, J., Zehnder, J. L.
2010; 12 (1): 58-64
- **Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms** *BRITISH JOURNAL OF HAEMATOLOGY*
Hidalgo-Curtis, C., Apperley, J. F., Stark, A., Jeng, M., Gotlib, J., Chase, A., Cross, N. C., Grand, F. H.
2010; 148 (2): 268-273
- **When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings** *AMERICAN JOURNAL OF HEMATOLOGY*
Pollyea, D. A., George, T. I., Corless, C., Gotlib, J.
2009; 84 (12): 843-846
- **On being metachromatic: mystique and misunderstanding in mastocytosis** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J.
2009; 84 (12): 779-781
- **NPM1 Haploinsufficiency Results in Increased Numbers of Hematopoietic Stem Cells and Progenitor Cells** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Raval, A., Park, C. Y., Pang, W. W., Kusler, B., Sridhar, K. J., Gotlib, J. R., Greenberg, P. L., Weissman, I. L., Mitchell, B. S.
AMER SOC HEMATOLOGY.2009: 307–
- **Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis**
Tyner, J. W., Fletcher, L., Yang, W., Oh, S. T., Gotlib, J. R., Deininger, M. W. N., Druker, B. J., Loriaux, M.
AMER SOC HEMATOLOGY.2009: 295–96
- **A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden**
Pardanani, A. D., Gotlib, J. R., Jamieson, C., Cortes, J., Talpaz, M., Stone, R., Silverman, M. H., Shorr, J., Gilliland, D., Tefferi, A.
AMER SOC HEMATOLOGY.2009: 314–15
- **AML Patients with Monosomal Karyotype Are Characterized by Absence of NPM1 and FLT3 Mutations and Worse Clinical Outcome.**
Seetharam, M., Weinberg, O. K., Ren, L., Ma, L., Seo, K., Zehnder, J. L., Gotlib, J. R., Arber, D. A.
AMER SOC HEMATOLOGY.2009: 1035
- **RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies**
Tyner, J. W., Loriaux, M., Willis, S. G., Chang, B. H., Bicocca, V. T., Oh, S. T., Hollink, I. M., Segers, S., DenBoer, M. L., van den Heuvel-Eibrink, M. M., Zwaan, C., Gotlib, J. R., Deininger, et al
AMER SOC HEMATOLOGY.2009: 1529
- **Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., Coutre, S., Medeiros, B. C., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2009: 646–47
- **Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., Medeiros, B. C.

AMER SOC HEMATOLOGY.2009: 420-21

- **Chronic Myelogenous Leukemia** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., Mughal, T., Mughal, T., Radich, et al
2009; 7 (9): 984-1023
- **NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.** *Journal of the National Comprehensive Cancer Network*
O'Brien, S., Berman, E., Borghaei, H., DeAngelo, D. J., Devetten, M. P., Devine, S., Erba, H. P., Gotlib, J., Jagasia, M., Moore, J. O., Mughal, T., Pinilla-Ibarz, J., Radich, et al
2009; 7 (9): 984-1023
- **Monoclonal antibodies against IREM-1: potential for targeted therapy of AML** *LEUKEMIA*
Korver, W., Zhao, X., Singh, S., Pardoux, C., Zhao, J., Guzman, M. L., Sen, S., Yonkovich, S., Liu, S., Zhan, X., Tomasevic, N., Zhou, C., Gros, et al
2009; 23 (9): 1587-1597
- **RNAi screen for rapid therapeutic target identification in leukemia patients** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Tyner, J. W., Deininger, M. W., Loriaux, M. M., Chang, B. H., Gotlib, J. R., Willis, S. G., Erickson, H., Kovacsics, T., O'Hare, T., Heinrich, M. C., Druker, B. J.
2009; 106 (21): 8695-8700
- **Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., Rajwanshi, R., Zehnder, J., Zehnder, J.
AMER SOC CLINICAL ONCOLOGY.2009
- **Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens** *NATURE MEDICINE*
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., O'Neill, R., Padua, R., Xu, L., Taketa, D., Shirer, A. E., Beer, S., Yee, A. X., Voehringer, et al
2009; 15 (5): 566-571
- **Glycogen synthase kinase 3 beta missplicing contributes to leukemia stem cell generation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Abrahamsson, A. E., Geron, I., Gotlib, J., Dao, K. T., Barroga, C. F., Newton, I. G., Giles, F. J., Durocher, J., Creusot, R. S., Karimi, M., Jones, C., Zehnder, J. L., Keating, et al
2009; 106 (10): 3925-3929
- **Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J. D., Gotlib, J., Zehnder, J. L., Arber, D. A.
AMER SOC HEMATOLOGY.2009: 1906-8
- **A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes** *AMERICAN JOURNAL OF HEMATOLOGY*
Gotlib, J., Lavori, P., Quesada, S., Stein, R. S., Shahnia, S., Greenberg, P. L.
2009; 84 (1): 15-20
- **Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System** *98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Weinberg, O. K., Seetharam, M., Ren, L., Ma, L., Seo, K., Merker, J., Gotlib, J., Zehnder, J., Arber, D. A.
NATURE PUBLISHING GROUP.2009: 291A-291A
- **Myelomastocytic Leukemia: A Clinical, Pathologic, and Molecular Genetic Study** *98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
McGuire, A., Shier, L. R., Gotlib, J., Medeiros, B., Wong, K., Corless, C., Arber, D. A., George, T. I.
NATURE PUBLISHING GROUP.2009: 277A-277A
- **Molecular stratification of patients with normal karyotype acute myeloid leukemia based on initial assessment of FLT3-internal tandem duplication status at first complete remission** *LEUKEMIA & LYMPHOMA*
Medeiros, B. C., Gotlib, J., Zehnder, J.
2009; 50 (5): 851-853

- **Clinical Characterization of Acute Myeloid Leukemia with Myelodysplasia-Related Changes as Defined by the 2008 WHO Classification System** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Weinberg, O. K., Seetharam, M., Ren, L., Ma, L., Seo, K., Merker, J. D., Gotlib, J. R., Zehnder, J. L., Arber, D. A.
AMER SOC HEMATOLOGY.2008: 341-42
- **Tailored Temozolomide Therapy for Elderly Patients with Acute Myeloid Leukemia.**
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Mignea, A., Zehnder, J.
AMER SOC HEMATOLOGY.2008: 351
- **A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis**
Pardanani, A. D., Gotlib, J., Jamieson, C., Cortes, J., Talpaz, M., Stone, R. M., Silverman, M. H., Shorr, J., Gilliland, D., Tefferi, A.
AMER SOC HEMATOLOGY.2008: 43-44
- **RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients**
Tyner, J. W., Loriaux, M., Willis, S. G., Chang, B., Bicocca, V. T., Oh, S., Hollink, I. M., Segers, S., den Boer, M. L., Zwaan, C. M., Gotlib, J. R., Deininger, M. W. N., Druker, et al
AMER SOC HEMATOLOGY.2008: 281
- **Small-Molecule Inhibitor Screen Rapidly Identifies Key Signaling Pathways in Leukemogenesis.**
Tyner, J. W., Erickson, H., Oh, S., Gotlib, J. R., Deininger, M. W. N., Druker, B. J., Loriaux, M.
AMER SOC HEMATOLOGY.2008: 874
- **Five years since the discovery of FIP1L1-PDGFR α : what we have learned about the fusion and other molecularly defined eosinophilias** *LEUKEMIA*
Gotlib, J., Cools, J.
2008; 22 (11): 1999-2010
- **Design and Validation of a Real-Time PCR Assay for Quantification of JAK2 V617F and Wild-type JAK2 Transcript Levels** *14th Annual Meeting of the Association-for-Molecular-Pathology*
Merker, J. D., Jones, C. D., Oh, S. T., Khan, S., Schrijver, I., Gotlib, J., Zehnder, J. L.
ELSEVIER SCIENCE INC.2008: 581-81
- **Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors** *CANCER CELL*
Geron, I., Abrahamsson, A. E., Barroga, C. F., Kavalchik, E., Gotlib, J., Hood, J. D., Durocher, J., Mak, C. C., Noronha, G., Soll, R. M., Tefferi, A., Kaushansky, K., Jamieson, et al
2008; 13 (4): 321-330
- **A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia** *BLOOD*
Raponi, M., Lancet, J. E., Fan, H., Dossey, L., Lee, G., Gojo, I., Feldman, E. J., Gotlib, J., Morris, L. E., Greenberg, P. L., Wright, J. J., Harousseau, J., Loewenberg, et al
2008; 111 (5): 2589-2596
- **Gene expression and pathway analysis of immune thrombocytopenic purpura** *BRITISH JOURNAL OF HAEMATOLOGY*
Sood, R., Wong, W., Gotlib, J., Jeng, M., Zehnder, J. L.
2008; 140 (1): 99-103
- **Significance of NPM1 and FLT3 mutations in acute myeloid leukemia with multilineage dysplasia: Does NPM1 identify a lower risk group?** *97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Weinberg, O., Merker, J., Beck, A., Seetharam, M., Gotlib, J., Zehnder, J., Arber, D. A.
NATURE PUBLISHING GROUP.2008: 281A-281A
- **Antiangiogenic therapy in myelodysplastic syndromes: is there a role?** *Current hematologic malignancy reports*
Oh, S. T., Gotlib, J.
2008; 3 (1): 10-18
- **Chronic eosinophilic leukemia/hypereosinophilic syndrome.** *Cancer treatment and research*
Gotlib, J.
2008; 142: 69-106
- **Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation** *49th Annual Meeting of the American-Society-of-Hematology*

- Abrahamsson, A., Geron, I., Gotlib, J., Dao, K., Giles, F., Newton, I., Kavaterchik, E., Durocher, J., Creusot, R., Karimi, M., Jones, C., Zehnder, J., Keating, et al
AMER SOC HEMATOLOGY.2007: 238A–239A
- **The KIT tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): Interim results of a phase II trial** *49th Annual Meeting of the American-Society-of-Hematology*
Gotlib, J., George, T. I., Corless, C., Linder, A., Ruddell, A., Akin, C., DeAngelo, D. J., Kepten, I., Lanza, C., Heinemann, H., Yin, O., Gallagher, N., Graubert, et al
AMER SOC HEMATOLOGY.2007: 1035A–1035A
 - **A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia** *BLOOD*
Lancet, J. E., Gojo, I., Gotlib, J., Feldman, E. J., Greer, J., Liesveld, J. L., Bruzek, L. M., Morris, L., Park, Y., Adjei, A. A., Kaufmann, S. H., Garrett-Mayer, E., Greenberg, et al
2007; 109 (4): 1387-1394
 - **Gene expression profile of idiopathic thrombocytopenic purpura (ITP) reveals elevated expression of interferon regulated genes.** *48th Annual Meeting of the American-Society-of-Hematology*
Sood, R., Wong, W., Gotlib, J., Jeng, M., Zehnder, J. L.
AMER SOC HEMATOLOGY.2006: 211A–211A
 - **Aberrant regulation of Wnt/beta-catenin pathway mediators in chronic myelogenous leukemia stem cells** *48th Annual Meeting of the American-Society-of-Hematology*
Abrahamsson, A., Geron, I., Gotlib, J., Durocher, J., Creusot, R., Kavalerchik, E., Goff, D., Fathman, C. G., Lilleberg, S. L., Giles, F., Weissman, I., Jamieson, C.
AMER SOC HEMATOLOGY.2006: 605A–605A
 - **Inhibition of JAK2 V617F-Induced erythroid skewing of hematopoietic stem cell differentiation with a selective JAK2 antagonist.** *48th Annual Meeting of the American-Society-of-Hematology*
Geron, I., Barroga, C., Gotlib, J., Kavalerchik, E., Abrahamsson, A., Goff, D., Cacalano, N., Hood, J., Soll, R., Noronha, G., Tefferi, A., Weissman, I. L., Kaushansky, et al
AMER SOC HEMATOLOGY.2006: 1033A–1033A
 - **Inhibition of chronic myelogenous leukemia stem cells with novel wnt antagonists.** *48th Annual Meeting of the American-Society-of-Hematology*
Kavalerchik, E., Gotlib, J., Geron, I., Abrahamsson, A., Wrasidlo, W., Goff, D., Lu, D., Molinski, T., Giles, F., Weissman, I., Carson, D., Jamieson, C.
AMER SOC HEMATOLOGY.2006: 74A–75A
 - **A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significance** *AMERICAN JOURNAL OF HEMATOLOGY*
Fukumoto, J. S., Gotlib, J.
2006; 81 (11): 870-874
 - **Use of urine flow cytometry to verify relapse of Burkitt's lymphoma in the genitourinary system** *JOURNAL OF CLINICAL ONCOLOGY*
Dormady, S. P., Mariappan, M. R., Kao, D., Gotlib, J.
2006; 24 (27): 4515-4516
 - **KIT mutations in mastocytosis and their potential as therapeutic targets** *IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA*
Gotlib, J.
2006; 26 (3): 575-?
 - **Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis** *JOURNAL OF MOLECULAR DIAGNOSTICS*
Lay, M., Mariappan, R., Gotlib, J., Dietz, L., Sebastian, S., Schrijver, I., Zehnder, J. L.
2006; 8 (3): 330-334
 - **Eosinophilic disorders: Molecular pathogenesis, new classification, and modern therapy** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
Gotlib, J., Cross, N. C., Gilliland, D. G.
2006; 19 (3): 535-569
 - **Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation** *BLOOD*

- Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S. L., Durocher, J. A., Lichy, J. H., Wang, Y. F., Cohen, et al
2005; 106 (8): 2865-2870
- **Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.** *Current hematology reports*
Gotlib, J.
2005; 4 (1): 77-84
 - **Molecular classification and pathogenesis of eosinophilic disorders: 2005 update** *ACTA HAEMATOLOGICA*
Gotlib, J.
2005; 114 (1): 7-25
 - **Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML** *NEW ENGLAND JOURNAL OF MEDICINE*
Jamieson, C. H., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., Sawyers, C. L., Weissman, I. L.
2004; 351 (7): 657-667
 - **Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.** *Seminars in cancer biology*
Coutre, S., Gotlib, J.
2004; 14 (4): 307-315
 - **The HP1L1-PD1GFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management** *BLOOD*
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., Coutre, S. E.
2004; 103 (8): 2879-2891
 - **Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis** *BLOOD*
Loh, M. L., Vattikuti, S., Schubert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., Cheng, J. W., Lee, C. M., Stokoe, D., Bonifas, J. M., Curtiss, N. P., Gotlib, J., Meshinchi, et al
2004; 103 (6): 2325-2331
 - **Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate** *SEMINARS IN CANCER BIOLOGY*
Coutre, S., Gotlib, J.
2004; 14 (1): 23-31
 - **PTPN11 mutations are rare in adult patients with chronic myelomonocytic leukemia (CMML).** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Loh, M. L., Vattikuti, S., Reynolds, M. G., Cheng, J. W., Lee, C. M., Gotlib, J., Beran, M.
AMER SOC HEMATOLOGY.2003: 328B-328B
 - **Novel biospecific agents for the treatment of myelodysplastic syndromes.** *Journal of the National Comprehensive Cancer Network*
Gotlib, J., Greenberg, P. L.
2003; 1 (4): 473-480
 - **Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study** *LEUKEMIA*
Deeg, H. J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., Appelbaum, F., Greenberg, P.
2002; 16 (2): 162-164